β-Cryptoxanthin inhibits the progression of NASH by attenuating lipid accumulation, lipid peroxidation, and insulin resistance as well as reducing the accumulation of T-cells and regulating the M1/M2 status of Kupffer cells in the liver, which occurs at least partly through a downregulation of the MCP-1-CCR2 and RANTES/CCL5-CCR5 pathways [62]. The gene discussed is CCL2; the disease is metabolic dysfunction-associated steatohepatitis.